Plexiform Neurofibroma — Variants & evidence

Plexiform Neurofibroma — Variants & evidence · CancerIndex

Variants & evidence

Curated clinical evidence by variant and therapy

3 evidence items mapped to this entity or its descendants, grouped by molecular profile, then therapy. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
NF1 Mutation3
Selumetinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID11176 In a pediatric phase 2 trial of the MEK inhibitor selumetinib (NCT01362803), partial responses were seen in 70% (35 of 50) children with neurofibromatosis type 1 and symptomatic inoperable plexiform n… (full text at CIViC) PMID 32187457 · Gross et al., 2020 · Open in CIViC	civic
〃	Predictive	A	Supports Sensitivity Response	3	accepted	EID1958 Treatment with selumetinib (NCT01362803) resulted in confirmed partial, long term responses in 17 of the 24 children with NF1 associated plexiform fibromas (71%) and decreases from baseline in neurofi… (full text at CIViC) PMID 28029918 · Dombi et al., 2016 · Open in CIViC	civic
〃	Predictive	B	Supports Sensitivity Response	4	submitted	EID7266 Patients with Neurofibromatosis 1, inoperable Plexiform Neurofibroma and disease related morbidity received selumetinib. Best response PR (36 pts, 72%), stable disease (12 pts, 24%); 2 subjects (4%) h… (full text at CIViC) Open in CIViC	civic

Data updated 10 minutes agoSource updated unknownsource: civic (CC0)

Evidence levels, directions and ratings are those assigned by CIViC curators. "Submitted" items have not completed curation review. This is not treatment guidance.